A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Amgen
- 07 Oct 2024 Planned End Date changed from 6 Aug 2038 to 7 Jan 2038.
- 07 Oct 2024 Planned primary completion date changed from 6 Aug 2038 to 7 Jan 2038.
- 14 May 2024 Planned End Date changed from 31 Aug 2037 to 6 Aug 2038.